The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN)

Best Pract Res Clin Obstet Gynaecol. 2003 Dec;17(6):905-23. doi: 10.1016/s1521-6934(03)00092-0.

Abstract

Gestational trophoblastic neoplasia (GTN) comprises a spectrum of disease from low-risk disease which can be cured with simple relatively non-toxic treatment, to extremely aggressive tumours which require specialized management. The prognostic variables in patients with GTN are different from those in other gynaecological malignancies, and the major adverse prognostic variables include long interval from antecedent pregnancy, high concentrations of the pregnancy hormone, human chorionic gonadotrophin, metastases in brain and liver and failure of prior treatment. Patients who relapse after their prior treatment can also be categorized into different risk groups. Salvage treatment can vary from single agent actinomycin D to combination chemotherapy and, in selected cases, surgery. With appropriate management, the majority of patients can achieve long-term remission and, in most cases, preserve fertility. The late side-effects of more intensive treatment are a small risk of inducing second tumours and also of bringing forward the age of menopause.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Central Nervous System Neoplasms / secondary
  • Chorionic Gonadotropin / blood
  • Drug Resistance, Neoplasm
  • Female
  • Gestational Trophoblastic Disease / drug therapy*
  • Gestational Trophoblastic Disease / genetics
  • Humans
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Staging
  • Pregnancy
  • Prognosis
  • Risk Factors
  • Treatment Outcome
  • Trophoblastic Tumor, Placental Site / therapy
  • Uterine Neoplasms / therapy

Substances

  • Antineoplastic Agents
  • Chorionic Gonadotropin